Impact des signatures moléculaires sur le choix du traitement systémique du cancer du rein métastatique
| Autor: | Cheng-Ming Sun, Marco Moreira, Audrey Simonaggio, Reza Elaidi, Nicolas Epaillard, Stéphane Oudard, Yann-Alexandre Vano |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Cancer Research Standard of care business.industry Immune checkpoint inhibitors Anti angiogenic Context (language use) Hematology General Medicine medicine.disease 03 medical and health sciences Clear cell renal cell carcinoma 030104 developmental biology 0302 clinical medicine Oncology 030220 oncology & carcinogenesis Carcinoma medicine Cancer research Radiology Nuclear Medicine and imaging business Tyrosine kinase Predictive biomarker |
| Zdroj: | Bulletin du Cancer. 107:S24-S34 |
| ISSN: | 0007-4551 |
| DOI: | 10.1016/s0007-4551(20)30275-7 |
| Popis: | The standard of care for metastatic clear cell renal cell carcinoma (mccRCC) has changed dramatically over the past decades thanks to the increasing number of treatments: anti-VEGFR tyrosine kinase inhibitors (TKI), mTOR inhibitors and immune checkpoint inhibitors (ICI): anti PD(L)-1 used as monotherapy or in combination with anti CTLA-4 or anti angiogenic therapies. In the face of rising therapeutic options, the question of the therapeutic sequences arises: which treatment for which patient? Actually, there is a lack of predictive biomarkers. A greater understanding of the cancer biology and its interaction with the microenvironment has allowed the development of genomic signatures which could perhaps be used as predictive biomarker. This review will give an insight on some robust genomic signatures assessed in mccRCC and will have a closer look at BIONIKK phase II trial, which is the first trial to adapt treatments according to the molecular characteristics of the tumor in the context of mccRCC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|